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Abstract
Thrombopoietin was posited to exist in 1958 and cloned in 1994, and in the ensuing two decades we have learned
a great deal about the physiology and pathology of the primary regulator of thrombopoiesis. This paper will review
the role of the hormone and its receptor, the product of the c-Mpl proto-oncogene, in health and disease, including
many unexpected effects in both normal and neoplastic hematopoiesis. Amongst these unexpected properties are a
non-redundant effect on hematopoietic stem cells, a critical role in all three of the acquired, chronic myeloproliferative
neoplasms, as well as both gain-of-function and loss-of-function mutations in congenital and acquired states of
thrombocytopenia and thrombocythemia.
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Background
The term thrombopoietin first appeared in the literature
in 1958 [1], to depict the primary regulator of platelet pro-
duction. Over the ensuing 36 years numerous attempts to
purify thrombopoietin were undertaken, but the identifi-
cation of the orphan cytokine receptor, c-Mpl, in France
in 1992 [2] catalyzed the successful cloning of the hor-
mone by three groups in 1994 [3]. Since that time the role
of thrombopoietin and c-Mpl has been evaluated exten-
sively in normal and neoplastic hematopoiesis [4]. This
paper will review that progress.
Review
The regulation of thrombopoietin
As the primary regulator of platelet production, it would
be anticipated that the levels of thrombopoietin would be
inversely related to blood platelet levels, and this is the
case in most pathological conditions [5]. Patients with
aplastic anemia have the highest levels of blood
thrombopoietin (~1-2 ng/ml) with normal values of ap-
proximately 80 pg/ml. Patients with chemotherapy-induced
thrombocytopenia have intermediate levels, although pa-
tients with immune thrombocytopenia have unexpectedly
relatively normal levels. A number of physiological mecha-
nisms account for these findings.
The liver is the largest single site of thrombopoietin
production, producing the hormone in both constitutive
and inducible fashion, a finding that helps to explain the
thrombocytopenia seen in patients with hepatic failure.
The baseline level of the hormone was thought to be
mediated by receptor-medicated removal of the hor-
mone from the circulation by platelets and/or marrow
megakaryocytes. Platelets express low levels of c-Mpl,
which take up thrombopoietin and degrade it [6]. This
“sponging” of the hormone is thought to be an import-
ant regulatory “governor” of platelet production. More
recently, this view has been challenged, with evidence
that it is due to the sensing of senescent platelets, medi-
ated by the hepatocyte Ashwell Morrell receptor [7],
which is stimulated by desialated proteins. In addition to
one or both of these mechanisms regulating platelet pro-
duction, hepatocytes can be induced to produce additional
thrombopoietin when stimulated by interleukin 6 [8], the
mechanism of thrombocytosis seen in patients with
chronic inflammatory conditions, such as ulcerative colitis
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or rheumatoid arthritis, the two most common causes of
thrombocytosis.
Additional mechanisms of thrombopoietin production
also exist; marrow stromal cells respond to
thrombocytopenia with increased production of the hor-
mone [9], and since the hormone acts in a paracrine
fashion (directly adjacent), rather than hepatic endocrine
hormone production (at a distance), one might assume
that the marrow stromal cell production may play a par-
ticularly important role in platelet production.
c-Mpl signal transduction
Once thrombopoietin binds to the c-Mpl receptor a
number of signaling pathways are triggered. Thrombo-
poietin binds to the extracellular domain of c-Mpl, indu-
cing dimerization of two copies of the receptor as the
hormone displays two receptor binding sites on its four
alpha helix tertiary fold, the A and D helix binding to
the first receptor, and the A and C helices binding to the
second receptor subunit [10]. Once the receptor dimer
is formed, it allows the Jak2 signaling kinase bound to
the membrane proximal region of the cytoplasmic do-
main to dimerize, allowing their cross phosphorylation
(activation) [11] and subsequent phosphorylation of the
membrane distal region of the cytoplasmic domain of
the receptor and a number of proteins that tether to the
newly generated phosphotyrosine sites of the receptor.
Amongst the signaling pathways activated are the
phosphoinositol-3-kinase [12], mitogen activated protein
kinase [13] and several microRNA pathways [14]. The
result is the alteration of a number of cell proliferation,
cell survival and cell differentiation processes.
Thrombopoietin and the hematopoietic stem cell
When initially defined as the primary regulator of
thrombopoiesis, most assumed that the effects of throm-
bopoietin were restricted to megakaryocyte and platelet
differentiation and maturation. The hormone was not
supposed to stimulate the proliferation of megakaryocyte
precursors, and definitely not support primitive hemato-
poietic cells at all. The availability of pure thrombopoie-
tin has dispelled these incorrect first assumptions.
Thrombopoietin is the most potent stimulator of mega-
karyocyte colony-forming cells [15], and is one of only
two non-redundant hormones that affect hematopoietic
stem cell survival and expansion (stem cell factor is the
other). The stem cell effects of thrombopoietin can be
demonstrated in vitro, with single cell culture ex-
periments [16], in vivo in knock out mice (e.g. genetic
elimination of c-Mpl or THPO reduce the number of
transplantable hematopoietic stem cells by 10-fold [17]),
and in people (missense or non-sense mutations of ei-
ther gene cause congenital amegakaryocytic throm-
bocytopenia that can evolve into aplastic anemia if the
mutation is severe [18]). Hence, c-Mpl is expressed in
hematopoietic stem cells, which provides the basis for
our, and others exploring the role of the cytokine and its
receptor in diseases of the hematopoietic stem cell.
Thrombopoietin, c-Mpl and the chronic myeloproliferative
neoplasms
In 1950 William Dameshek postulated that the three
chronic myeloproliferative neoplasms (then called syn-
dromes), polycythemia vera, essential thrombocythemia
and primary myelofibrosis were pathophysiologically re-
lated [19]. It took 55 years to provide a molecular ex-
planation for this correct hypothesis. In 2005 four
groups reported that virtually every patient with polycy-
themia vera, and about half of patients with essential
thrombocythemia and primary myelofibrosis display one
or two (exclusively P. vera patients) mutant alleles of the
signaling kinase Jak2 [20–23]. The valine to phenylalan-
ine at position 617 in the “pseudokinase” domain of Jak2
causes autonomous signaling. It has been postulated that
the mutation changes the activation loop interaction
with the kinase domain, although other mechanisms by
which this point mutation might activate the kinase are
being considered (e.g. spontaneous dimerization of the
mutant Jak2), especially since other site mutations in the
Jak2 kinase are also associated with/causative of myelo-
proliferative neoplasms.
Soon after description of the Jak2V617F mutation in the
chronic myeloproliferative neoplasms, attention turned to
non-Jak2V617F bearing diseases. A year later an activating
mutation of the c-Mpl receptor was described, at position
c-Mpl515 [24], which when transduced into marrow cells
produced an aggressive myeloproliferative syndrome in
animals. Overall, about 5–10 % of patients with essential
thrombocythemia or primary myelofibrosis express this
mutant form of the thrombopoietin receptor. A number
of other patients were also shown to harbor mutations in
a series of genes that affect epigenetic modifications of
hematopoietic cells, such as Tet2 and several methylation
modification enzymes. Altogether these mutations provide
a molecular explanation for approximately 5–10 % add-
itional patients with a non-Jak2V617F-bearing disease.
And most recently, a full 30 % of patients lacking
Jak2V617F display a truncation mutation of the endoplas-
mic reticulum chaperone and calcium buffering protein
called calreticulin [25]. Elimination of the carboxyl ter-
minus of this protein removes an endoplasmic reticulum
retention signal, allowing the protein to travel to other
sites in the cell.
Twenty years ago Li and colleagues described that one
of the hallmarks of myeloproliferative neoplasms, spon-
taneous colony formation, was significantly reduced by
reduction in expression of c-Mpl in marrow cells using
an antisense oligonucleotide strategy [26]. This finding
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raises the question of whether c-Mpl might play an im-
portant role in all patients with acquired myeloprolifera-
tive neoplasms, and if so, what is it’s mechanism.
As described above, the signaling kinase Jak2 acts by
binding to the cytoplasmic domain of c-Mpl and from
there is dimerized when thrombopoietin binds to the re-
ceptor. So the question arose as to whether Jak2 binding
to any cytokine receptor might serve as a scaffold to
allow Jak2 dimerization. This question was addressed by
our laboratory and others, and the conclusion is that any
receptor that homodimerizes (as opposed to heterodi-
merization, as occurs with the IL-3 or GM-CSF recep-
tor) can serve to support Jak2V617F-induced-growth
factor independent cell growth [27]. Since the receptors
for erythropoietin, granulocyte colony stimulating factor
and thrombopoietin are all homodimers, theoretically
Jak2V617F should be able to induce cytokine independ-
ent growth in cells expressing any of these three recep-
tors. However, as mentioned above, that while c-Mpl is a
bone fide stem cell receptor, neither the erythropoietin
or the G-CSF receptors are expressed in hematopoietic
stem cells.
In order to prove that c-Mpl is required for Jak2V617F
induced myeloproliferative neoplasm, we and others
have now created mouse models of myeloproliferation
and crossed the mice with those null for c-Mpl. In our
studies the expected rise in neutrophil and platelet
counts, expansion of all types of hematopoietic colony
forming cell types, splenomegaly and osteosclerosis were
all eliminated in the Jak2V617F bearing mice that were
also null for c-Mpl [28].
Finally, very recent data suggests that the myeloprolif-
erative neoplasm induced by truncation mutations of
calreticulin also require c-Mpl to induce disease; in this
case, elimination of the endoplasmic reticulum tether al-
lows calreticulin to bind to c-Mpl and travel to the cell
membrane where the thrombopoietin receptor dimerizes
and drives Jak2 activation [29].
Conclusions
Since their cloning 22 years ago thrombopoietin and its
receptor, the product of the c-Mpl proto-oncogene, have
been extensively characterized, the physiology of hema-
topoiesis is now much better understood, small molecule
receptor binding agonists produced and approved for
clinical use, and the role of the hormone and receptor in
human health and disease defined. Both congenital and
acquired mutations of the hormone and its receptor
cause either familial thrombocytosis and thrombo-
cytopenia/aplastic anemia, depending on whether the
mutations are loss of function or gain of function, and
more recently the normal receptor was found to play a
critical role in virtually all patients with chronic myelo-
proliferative neoplasms. These insights should lead to
novel and improved therapeutic approaches to a range
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